Antimicrobial agents have unquestionable importance in the control of many diseases; however the constant preoccupation with the evolution of resistant microorganisms is increasing. Carbapenems are ²-lactam antimicrobials broad-spectrum resistant to hydrolysis of ²-lactamases, which is the main mechanism of resistance of many microorganisms. Ertapenem sodium is a synthetic antimicrobial agent of the class of carbapenems commercially available in the form of lyophilized powder for solution for injection, under the commercial name INVANZ® by Merck Sharp & Dohme. It shows action against Gram-negative, Gram-positive, aerobic and anaerobic microorganisms. Its mechanism of action results from inhibition of cell wall synthesis. Studies on antimicrobial activity, pharmacokinetics and pharmacodynamics for ertapenem are presented in the literature, however there are few studies reported related to the development of analytical methods applied to quality control. Therefore, research involving the development of methodologies for the characterization and quantification of this drug, giving priority for ease of implementation, reduced analysis time and reducing the use of organic solvents, are of high importance to ensure the quality of the marketed product since sustainability has been discussed and encouraged globally. Thereat, this work proposes the development of new methods for analysis of ertapenem in pharmaceutical formulation using spectrophotometry in the regions of ultraviolet and infrared, high performance liquid chromatography, microbiological assay and capillary electrophoresis, as well as conducting studies of polymorphic forms that will be held at the National University of Cordoba - Argentina.
News published in Agência FAPESP Newsletter about the scholarship: